Abbott Labs has spun off its specialty drug division into a new company called AbbVie, which the new company's leaders heralded Wednesday by ringing the first opening bell of 2013 at the New York Stock Exchange.
According to a Bloomberg report, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion.
According to "Nutritional Supplements in the U.S.," a report released earlier this week from Packaged Facts, supplement sales rose 7% to $11.5 billion in 2012, and are forecasted to reach $15.5 billion by 2017.
A large number of patients with a serious form of arthritis experienced improvement in their condition after taking a drug made by Abbott Labs for three months, according to results of a late-stage clinical trial announced Monday.
The National Advertising Division of the Council of Better Business Bureaus last week determined Abbott Nutrition could support certain advertising claims made for Similac Advance and Similac Sensitive infant formula. However, NAD recommended that Abbott modify or discontinue certain other claims.